0M2N.LSE Orion Oyj Series A

Healthcare Oil, Gas & Consumable Fuels London Exchange
61.56 EUR
Close of Nov 3, 2026
56.50 100.20
Market cap
EUR 8.66B
P/E
73.4x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2021.

Is 0M2N.LSE undervalued?

Graham number

The Graham number of Orion Oyj Series A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orion Oyj Series A fundamental analysis

No fundamental analysis for Orion Oyj Series A yet.

Orion Oyj Series A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orion Oyj Series A

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart fa…

Full company profile